Biomoti

biomoti exists to transform the treatment of cancer patients by doing things differently. oncojans™ are a new class of immunotherapeutic drug-loaded particles that target and gain entry to the tumour vasculature and cancer cells. they do this by taking advantage of the cd95l surface ligand that is selectively and heavily expressed in tumour vasculature and cancer cells but not healthy tissue. cd95l promotes tumour immune evasion, cancer cell proliferation and metastasis. it is an essential gene for cancer survival and promotes cancer stem cells. high levels of cd95l expression in patient tumours are associated with increased malignancy and poor prognosis. once inside cd95l+ve tumour cells, oncojans™ slowly release therapeutic drugs at the point of need whilst sparing healthy tissue. the oncojan™ platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.